[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362210-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362210-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-phase-iv-prospective-study-of-efficacy-and-safety-of-ribociclib-and-letrozole-as-first-line-therapy-in-older-women-70-years-with-hormone-receptor-positive-her2-negative-advanced-breast-cancer-the-ribob-study","A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer - the RibOB study","","Cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy are standard first-line treatment for hormone receptor-positive metastatic breast cancer, yet older patients (especially frail subgroups) remain underrepresented in trials. The RibOB phase IV open-label single-arm prospective study evaluated ribociclib 600 mg on a 3-weeks-out-of-4 schedule with letrozole in women ≥70 years. Primary endpoint was progression-free survival; secondary endpoints included safety, functional evolution and quality of life, and results by clinical frailty assessed by G8.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-phase-iv-prospective-study-of-efficacy-and-safety-of-ribociclib-and-letrozole-as-first-line-therapy-in-older-women-70-years-with-hormone-receptor-positive-her2-negative-advanced-breast-cancer-the-ribob-study/362210/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-phase-iv-prospective-study-of-efficacy-and-safety-of-ribociclib-and-letrozole-as-first-line-therapy-in-older-women-70-years-with-hormone-receptor-positive-her2-negative-advanced-breast-cancer-the-ribob-study/362210.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the RibOB study design and population?","Question",{"text":63,"@type":64},"The RibOB study is a phase IV open-label, single-arm prospective trial in women aged ≥70 with hormone receptor-positive, HER2-negative advanced breast cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What were the primary and key secondary endpoints?",{"text":68,"@type":64},"Progression-free survival (PFS) was the primary endpoint. Secondary endpoints included safety, functional evolution and quality of life (QoL), plus outcomes stratified by clinical frailty assessed by G8.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about efficacy and safety across frailty levels?",{"text":72,"@type":64},"Median PFS was 36 months and efficacy showed no significant differences between fit and frail patients. Adverse events were frequent, with grade 3 or higher events largely including neutropenia, and many patients required dose reductions or early discontinuation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362210,1790189087,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","ORIGINAL ARTICLE  \nA phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: the RibOB study  \nM. Van Houdt1†∗, C. Kenis2 , 3 , 4†, L. De Nys5, S. Hatse6, P. Neven1, A. Laenen7, J. Mebis8, E. de Azambuja9, N. F. Ponde10, L. Decoster11, C. Quaghebeur12, F. Cornelis13, D. M. E. C. Verhoeven14, A. Barbeaux15, V. Verschaeve16 & H. Wildiers2  \n1Department of Gynaecological Oncology/Multidisciplinary Breast Center, UZ Leuven―University Hospitals Leuven―Campus Gasthuisberg, Leuven; 2Department of General Medical Oncology, University Hospitals Leuven, Leuven; 3Department of Geriatric Medicine, University Hospitals Leuven, Leuven; 4Department of Public Health and Primary Care, Academic Centre for Nursing and Midwifery, KU Leuven―University of Leuven, Leuven; 5KU Leuven, UZ Leuven―University Hospitals Leuven―Campus Gasthuisberg, Leuven; 6Oncology, KU Leuven―Laboratory of Experimental Oncology, Leuven; 7Interuniversity Institute for Biostatistics and Statistical Bioinformatics, KU Leuven, Leuven; 8Department of Medical Oncology, Jesse Ziekenhuis―Campus Virga Jesse, Hasselt; 9Medical Oncology Department, Institute Jules Bordet, Hopital universitaire de Bruxelles (HUB), Universite libre de Bruxelles (ULB), Brussels, Belgium; 10Clinical Development, Daiichi Sankyo, Inc., Basking Ridge, USA; 11Department of Medical Oncology, UZ Brussel―Universitair Ziekenhuis Brussel, Jette; 12Department of Medical Oncology, CHU UCL Namur site Sainte-Elisabeth, Namur; 13Department of Medical Oncology, Cliniques Universitaires Saint-Luc (UCLouvain), Woluwe-Saint-Lambert, Brussels; 14Department of Medical Oncology, AZ Klina, Brasschaat; 15Department of Medical Oncology, CHR Verviers, Verviers; 16Medical Oncology Department, GHdC―Grand Hopital de Charleroi―Site Les Viviers, Charleroi, Belgium  \nAvailable online 08 January 2026  \nBackground: Cyclin-dependent kinase 4/6 inhibitors with endocrine therapy are standard first-line therapy for patients with hormone receptor-positive metastatic breast cancer. Older patients, especially the frailer subpopulation, are underrepresented in clinical trials, limiting data on treatment and safety outcomes in this population.  \nPatients and methods: The RibOB study was an open-label, single-arm phase IV prospective trial evaluating first-line ribociclib 600 mg 3 weeks out of 4 with letrozole in women ≥70 years with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Primary endpoint was progression-free survival (PFS) . Secondary endpoints were safety, functional evolution and quality of life (QoL), and outcomes in relation to clinical frailty assessed by G8 .  \nResults: Seventy patients were enrolled: median age 76 years, with 30% ≥80 years. Forty-five out of 70 patients had a G8 score of ≤14 (frail) at baseline. With a median follow-up of 30.5 months, the median PFS was 36 months (95% confidence interval 24 months-not estimable) . Median overall survival rate was not reached and breast cancerspecific survival rate at 24 and 36 months was 82% and 75%, respectively. Median time to treatment failure was 14.6 months. There were no significant differences in efficacy between fit and frail patients. Forty-seven out of 70 patients (67%) had grade 3 or higher adverse events, most commonly neutropenia (47%) . Liver toxicity grade 3 or higher occurred in 2/70 (3%), and grade 3 or higher QT prolongation in 3/70 (4%) . Thirty out of 70 patients (43%) discontinued ribociclib before progression and 57% required dose reductions to 400 mg, and 23% to 200 mg. Only 14 patients (20%) continued with the full 600-mg dose until end of study, disease progression, or death. No significant change in mean QoL was observed over time.  \nConclusion: Ribociclib in combination with letrozole showed clear antitumor efficacy and safe treatment option in older patients wit","cbCaipeq49ehkxCR","https://ap.wps.com/l/cbCaipeq49ehkxCR","pdf",912209,12,"English","# Patients and methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What is the RibOB study design and population?\",\"answer\":\"The RibOB study is a phase IV open-label, single-arm prospective trial in women aged ≥70 with hormone receptor-positive, HER2-negative advanced breast cancer.\"},{\"question\":\"What were the primary and key secondary endpoints?\",\"answer\":\"Progression-free survival (PFS) was the primary endpoint. Secondary endpoints included safety, functional evolution and quality of life (QoL), plus outcomes stratified by clinical frailty assessed by G8.\"},{\"question\":\"What did the study find about efficacy and safety across frailty levels?\",\"answer\":\"Median PFS was 36 months and efficacy showed no significant differences between fit and frail patients. Adverse events were frequent, with grade 3 or higher events largely including neutropenia, and many patients required dose reductions or early discontinuation.\"}]","A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer - the RibOB study | PDF",1790146788,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eefa752a83b2037c195e07cbb608d22d.webp",983,1269,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9c80a633155a23d0f55c6e05112c738.webp",982,1268,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34386770e6b3673b882b3671fcb288d5.webp",981,1266,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba4be5c1aceda8be9a07a9bcf6a358a6.webp",980,1265]